EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes

Zhi Du, Chengman Zhao, Jiabin Li, Yan Shen, Guofei Ren, Jieying Ding, Jing Peng, Xiaoli Ye, Jing Miao

PeerJ · 2025

DOI: 10.7717/peerj.19223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Zhi Du und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zh…. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Ginsenosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, The State Administration of Traditional Chinese Medicine and the Zhejiang Province jointly build Science and Technology Program, The Key Program of the Independent Design Project of National Clinical Research Center for Child Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with poorly understood mechanisms. Variations in gut microbiota composition are observed in different IBS subtypes. Ginsenosides have shown potential in alleviating IBS symptoms, but their interactions with gut microbiota in different IBS subtypes are not well studied.

Methods

In this study, we investigated the effects of ginsenosides on the gut microbiota of both healthy participants and participants suffering from IBS characterized by diarrhea (IBS-D) or constipation (IBS-C), using in vitro fermentation alongside 16S rRNA sequencing and bioinformatics analyses.

Results

The analysis demonstrated that there were no statistically significant alterations in α- or β-diversity between the ginsenosides-treated and control groups across all models. However, the microbial composition assessment revealed the presence of 51 shared genera, with notable variations in composition and a significant enrichment of specific taxa. Specifically, the LEfSe analysis revealed that, following ginsenosides treatment, the healthy model groups exhibited significant enrichment of Stenotrophomonas and Achromobacter , while the IBS-D model groups demonstrated significant enrichment of Pseudomonas and Stenotrophomonas .

Conclusions

The results elucidate the distinctive microbial signatures associated with ginsenosides treatment across both healthy and IBS-D groups, underscoring the potential therapeutic efficacy of ginsenosides in modulating gut microbiota. This study highlights the necessity for further investigation into targeted microbiome therapies for IBS, which may facilitate the development of more personalized and efficacious treatment strategies for gastrointestinal health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGastrointestinal MicrobiomeGinsenosidesHumansAdultMaleFemaleRNA, Ribosomal, 16SMiddle AgedDiarrheaHealthy VolunteersYoung AdultFeces

Stichwörter der Autor:innen

16S rRNAGinsenosidesGut microbiotaIn vitro fermentationIrritable bowel syndrome

Substanzen

GinsenosidesRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.
  • Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
  • Department of Gastroenterology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Department of Pharmacy, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Department of Medical Administration, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China.

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • The State Administration of Traditional Chinese Medicine and the Zhejiang Province jointly build Science and Technology Program
  • The Key Program of the Independent Design Project of National Clinical Research Center for Child Health

Zitieren

APA

Du, Z., Zhao, C., Li, J., Shen, Y., Ren, G., Ding, J., Peng, J., Ye, X., & Miao, J. (2025). Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes. PeerJ. https://doi.org/10.7717/peerj.19223

Vancouver

Du Z, Zhao C, Li J, Shen Y, Ren G, Ding J, et al. Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes. PeerJ. 2025. doi:10.7717/peerj.19223

BibTeX
@article{Du2025,
  author = {Du, Zhi and Zhao, Chengman and Li, Jiabin and Shen, Yan and Ren, Guofei and Ding, Jieying and Peng, Jing and Ye, Xiaoli and Miao, Jing},
  title = {Ginsenosides and gut microbiota: differential effects on healthy individuals and irritable bowel syndrome subtypes},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.19223}
}
Kostenlos starten →